Become A Research Partner

National Brain Tumor Society funds only the most promising research poised to deliver results. Our funded research has contributed to the establishment of many of what are now the top adult and pediatric brain tumor research labs across the country, as well as advances in understanding brain tumor makeup and what could drive more effective treatments.

By partnering with us and supporting our strategic initiatives, you can help advance the understanding of brain tumors, improve the availability of new treatments, and drive the discovery of a cure. Learn more about the initiatives that you can contribute to directly.

Defeat GBM

Glioblastoma multiforme (GBM) is a highly aggressive, complex, and devastating form of brain cancer, effecting hundreds of people each day. We believe it is our duty to accelerate progress against this disease so we launched the Defeat GBM Research Collaborative in 2013 with the intent to double the 5 year survival rate of GBM patients. This comes at a time when collaboration is becoming the norm and the abundance of genomic data is accelerating diagnostic, prognostic, and therapeutic progress.

Oligo Research Fund

Oligodendroglioma (oligo) is a relatively rare brain tumor representing about 6% of gliomas, with a diagnosis rate of about 1,150 patients a year in the U.S. alone. Critical research is required to deliver oligo patients new therapies that are more durable and extend their lives. In order to make effective, targeted therapies a reality it is essential to identify and understand the molecular drivers of the tumor’s genesis and maintenance, as well as resistance.

Defeat Pediatric Brain Tumors Research Collaborative

The Defeat Pediatric Brain Tumors Research Collaborative is a powerful, unique global research and drug discovery program which aims to improve clinical outcomes for pediatric brain tumor patients – and ultimately find a cure for brain tumors to save these kids.

Community Research

The Community Research Fund allows contributors to pool donations to support research on a specific type of tumor. This program leverages a team of highly experienced, nationally-recognized scientific experts, working with National Brain Tumor Society staff, to determine the best investment strategy for each fund.


From the Blog

  • January 14, 2021

    NBTS Brain Tumor Clinical Trials Report: Q4 2020

    It can be hard to keep track of new clinical trial opportunities opening across the United States, especially during the current public health crisis created by the coronavirus (COVID-19). However, there are many clinical trials still actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for […]

    The post Read More

  • January 7, 2021

    New Treatment Arms Opening for Patients in NBTS-Funded GBM AGILE Clinical Trial

    Yesterday, it was announced that the GBM AGILE adaptive clinical trial platform is opening two new treatment arms, with one evaluating Kintara Therapeutics’s chemotherapy, VAL-083, and Kazia Therapeutics’s targeted therapy, paxalisib.  “NBTS has long supported GBM AGILE as a scientifically cutting-edge and more patient-friendly way to develop and evaluate emerging new treatments for pati

    Read More

  • December 19, 2020

    4 Big Takeaways From the 2020 Annual Meeting of the Society for Neuro-Oncology

    A move to a virtual platform didn’t diminish the quality of the 2020 Annual Meeting of the Society for Neuro-Oncology (SNO), the yearly gathering of the world’s foremost brain tumor researchers and clinicians. As usual, the National Brain Tumor Society was a proud platinum sponsor of this important conference and deployed our own team of […]

    The post Read More

More from the blog